Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose inactivated vaccines followed by BNT162b2 booster
TCTR20220330001Phase 2Completed
- Sponsor
- National Vaccine Institute
- Start
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by National Vaccine Institute. Started Apr 2022; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20220330001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220330001.